ReviewKidney & blood pressure research2025
Predicting long-term kidney graft failure using novel multi-omic blood-based biomarkers and artificial intelligence tools.
Review in Kidney & blood pressure research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rejection-Focused Precision Medicine in Kidney Transplantation: Biology, Biomarkers, and Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplantation (KT) remains the preferred treatment for end-stage renal disease. With advancements in immunosuppressive regimens and KT surveillance, graft survival has improved, though mainly in short-term. Meanwhile, aging populations with multimorbidity and expanding donor criteria shape a new landscape for KT management. Numerous prediction tools, including genomic, transcriptomic and/or proteomic panels or biomarkers, have been developed for short-to-interim outcomes, yet variable outcome definitions, modest samples and limited external replication preclude clinical utility. The temporal nature of association strength for graft failure risk factors reflects changes in underlying pathomechanisms and underscores the need for extensive validation. Chronic allograft rejection is a progressive process intertwined with variable T cell and antibody-mediated rejection patterns. On a molecular level, both innate and adaptive immune cells interface within the local graft microenvironment and release donor cell products (eg, exosomes, peptides, apoptotic bodies) that prime both T and B cell, but also IFNγ driven NK cell-mediated responses. Complement and Ig deposits along capillary lining lead to activated endothelium that promotes immune cell influx and aberrant differentiation patterns. Under cytokine and growth factor stimulation, mesenchymal transition of graft epithelial cells leads to altered extracellular turnover and TGFβ-mediated fibrosis. These mechanistic processes remain incompletely understood but represent a biologically plausible source for urine/blood biomarkers and omic profiling. Artifical intelligence and machine-learning tools provides a promise for elucidating the nature of these mechanisms due to their ability to capture non-linear trends and complex interactions. However, early efforts still remain unsatisfactory as the data demand increases, with concomitant requirements for high feature quality and sample representativeness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.